CEE321

CEE321 is a potent pan-Janus kinase (JAK) inhibitor developed as a topical "soft drug" for the treatment of inflammatory skin diseases, particularly atopic dermatitis. It inhibits JAK1, JAK2, JAK3, and TYK2 with an IC50 of 54 nM in enzyme assays. Unlike systemically administered JAK inhibitors that can cause significant side effects due to systemic exposure, CEE321 was designed to have high clearance and limited systemic absorption when applied topically. This property allows it to exert its anti-inflammatory effects locally in the skin while minimizing systemic risks. In preclinical studies and ex vivo human skin models stimulated with IL4 and IL13 cytokines (relevant to atopic dermatitis), CEE321 potently inhibited disease biomarkers. The drug advanced into phase 1 clinical trials but was discontinued by Novartis after early data indicated an unfavorable risk-benefit profile[4][7][8].